{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:16:02Z","timestamp":1778541362843,"version":"3.51.4"},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geburtshilfe Frauenheilkd"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This consensus paper depicts prevention, identification, treatment, and the involvement of relevant medical specialists and other health care professionals in the management of defined side effects of the new selective oral PI3K inhibitor inavolisib. All topics were discussed and agreed upon between experts in oncology, gynecology, and diabetology from both clinical and private practice. In addition to a brief summary of the assumed pathomechanism of each selected side effect, the management of the defined adverse effects is described, based on respective severity and according to the summary of product characteristics (SmPC). These details are supplemented by the expertise and experience of the participating experts regarding possible preventative and supportive therapeutic measures, special precautions, and practical recommendations for daily clinical practice and patient management.<\/jats:p>","DOI":"10.1055\/a-2821-5278","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:51:41Z","timestamp":1776207101000},"page":"433-442","source":"Crossref","is-referenced-by-count":0,"title":["Consensus on the Management of Inavolisib Side Effects. A Survey on Defined Side Effects, the Assumed Pathomechanism, Preventative and\/or Therapeutic Measures Including the Integration of Additional Health Care Professionals \u2013 a Consensus Paper"],"prefix":"10.1055","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-430X","authenticated-orcid":false,"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, BW, Germany","place":["Heidelberg"],"department":["Division of Gynecologic Oncology, Department of Medical Oncology"]},{"name":"and the Thorax Clinic Heidelberg, Germany and German Cancer Research Center (DKFZ), BW, Germany","place":["Heidelberg"],"department":["the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University, National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"M\u00fcller-R\u00f6sel","sequence":"additional","affiliation":[{"name":"Klinikum G\u00fctersloh gGmbH, NRW, Germany","place":["G\u00fctersloh"],"department":["Diabetologie"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjoung-Won","family":"Park-Simon","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover Klinikum, NDS, Germany","place":["Hannover"],"department":["Klinik f\u00fcr Frauenheilkunde und Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Mannheim, BW, Germany","place":["Mannheim"],"department":["Frauenklinik, interdisziplin\u00e4res Brustzentrum"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Scheffen","sequence":"additional","affiliation":[{"name":"Evangelisches Krankenhaus Bethesda Monchengladbach gGmbH, NRW, Germany","place":["M\u00f6nchengladbach"],"department":["Brustzentrum Niederrhein"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"Klinikum Aschaffenburg-Alzenau Standort Aschaffenburg, BY, Germany","place":["Aschaffenburg"],"department":["MVZ am Klinikum Aschaffenburg, Zweigpraxis f\u00fcr H\u00e4matologie und Onkologie"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"S 16","key":"ref3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1200\/JCO.2024.42.16_suppl.1003","article-title":"First-line inavolisib\/placebo + palbociclib + fulvestrant (Inavo\/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced\/metastatic breast cancer who relapsed during\/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses","volume":"42","author":"D Juric","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/cancers14071598","article-title":"Management Strategies for Hyperglycemia Associated with the \u03b1-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer","volume":"14","author":"T Tankova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/15347354211073163","article-title":"Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia","volume":"21","author":"MD Goncalves","year":"2022","journal-title":"Integr Cancer Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102520","article-title":"Preventing alpelisib-related hyperglycaemia in HR+\/HER2\u2212\/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial","volume":"71","author":"A Llombart-Cussac","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"S 10","key":"ref8","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"SE Nunnery","year":"2019","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27531","article-title":"Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors","volume":"10","author":"J Liu","year":"2024","journal-title":"Heliyon"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","article-title":"Dermatologic adverse events related to the PI3K\u03b1 inhibitor alpelisib (BYL719) in patients with breast cancer","volume":"183","author":"DG Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105303","article-title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","volume":"10","author":"V Gambardella","year":"2025","journal-title":"ESMO Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"NC Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","volume-title":"5.3.6 Verbrennungstiefe","author":"S Ruchholtz","DOI":"10.1055\/b-0034-62191"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41419-022-04963-x","article-title":"The role of the PI3K\/AKT signalling pathway in the corneal epithelium: recent updates","volume":"13","author":"K Chen","year":"2022","journal-title":"Cell Death Dis"}],"container-title":["Geburtshilfe und Frauenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2821-5278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:36:50Z","timestamp":1778539010000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2821-5278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":11,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2821-5278","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0016-5751","1438-8804"],"issn-type":[{"value":"0016-5751","type":"print"},{"value":"1438-8804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}